H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best biotech stocks to buy. On September 16, H.C. Wainwright reaffirmed its $50 price target and Buy rating for Summit Therapeutics Inc.
Daily

India's pharma exports expected to cross USD 30 billion by this year end: Dr Jitendra Singh

New Delhi: India's pharma exports, currently valued at nearly $27.8 billion, are expected to cross $30 billion by this year end, Union Minister of State (Independent Charge) for Science and Technology ...
The Business Standard

Vaccine plant cost rises Tk385cr before shifting from Gopalganj to Munshiganj

Amid the decision to shift the country's first vaccine plant from Gopalganj to Munshiganj, the project cost has risen by Tk385 crore (12.77%). The Essential Drugs Company Limited, in its revised ...